Welcome to the 4th Mitochondrial Dysfunction Drug Development Summit
Uncover Mitochondrial Pathogenic Mechanisms & Validate Biomarkers to Demonstrate Clinical Efficacy for Regulatory Success
In light of Anavex Life Sciences’ promising drug candidate (ANAVEX3-71), coupled with Mission Therapeutics’ recent fundraising of £25.2 million to advance their mitophagy program (MTX325), there has been growing evidence of interest towards broader disease groups with underlying pathogenesis from mitochondrial dysfunction.
This November, we will reunite 60+ C-Level, Biologist, Preclinical, Translational and Innovation-Scouting Leaders who are building on from the industry’s latest setbacks to innovate mitochondria-targeting approaches and expand novel therapeutic opportunities.
From cutting-edge research backed by academia to transformative pipeline updates from preclinical and clinical settings revealed by the industry, this is your chance to get involved and de-risk clinical development of patient-centered therapeutics through the discovery and validation of biomarkers for defined endpoints.
Your Expert Speakers Include:
Dima Martini
Lead- Global Early-Stage Medical Affairs, Mitochondrial and Rare Disease
Astellas Pharma
Previous Attending Companies:
Hear From Our 2023 Attendees:
“Learning from others in the mitochondria space is extremely valuable as this has been challenging for drug development, but shows tremendous potential”
Capacity Bio
Our Partners:
Other Events in the Series:
